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Autologous Marrow and Recombinant Human Granulocyte-Macrophage 
Colony-Stimulating Factor After High-Dose Cyclophosphamide, 
Etoposide, and Cisplatin 
By  Susan D. Huan, Jean Hester, Gary Spitzer, Jonathan C. Yau, Frank R.  Dunphy, Ralph 0.  Wallerstein, Karel Dicke, 
Verneeda Spencer, Charles F. LeMaistre, Borje S. Andersson, Albert B.  Deisseroth, and Gerard J. Ventura 
Peripheral blood cells (PBC) can hasten hematopoietic recov- 
ery  after  high-dose  chemotherapy.  To  determine  if  PBC 
apheresed after mobilization further enhance hematopoietic 
recovery over that achieved with autologous bone marrow 
(ABM) and recombinant human granulocyte-macrophage col- 
ony-stimulating factor (rhGM-CSF),  14 patients with meta- 
static solid tumors were supported by ABM and rhGM-CSF 
during the first course of high doses of cyclophosphamide, 
etoposide, and cisplatin (CVP) and 11 of these 14 patients by 
mobilized PBC with ABM and rhGM-CSF during the second 
CVP. Each patient served as his or her own control. Identical 
doses of CVP were administered in both  courses: cyclophos- 
phamide 5.25 g/m2,  etoposide 1,200  mg/m2, and cisplatin 
165 to 180  mg/m2. PBC  were collected on day  10  after 
mobilization  with cyclophosphamide (3 g/m2) intravenously 
(IV) on day 1,  doxorubicin  (50 mg/m2) as a continuous IV 
infusion over 48 hours starting day 2,  and rhGM-CSF as a 
daily 4-hour IV infusion starting day 4 at 0.6 mg/m2  for 14 
ERIPHERAL BLOOD cells (PBC) have been shown  P  to reconstitute hematopoiesis after high-dose chemo- 
It has become a suitable alternative  to autolo- 
gous bone marrow (ABM) transplantation for patients who 
have  BM  involvement by  tumor,  prior  pelvic radiation, 
pelvic bone abnormality, or comorbid medical conditions 
that preclude their ability to undergo general anesthesia.6 
Apheresis of  PBC performed at the steady state is associ- 
ated with  slower re~overy.~  However, PBC enriched  for 
committed progenitors resulted  in  faster neutrophil  and 
platelet recovery.8-12  Numerous means have been explored 
to enrich  the circulating  progenitor  cells for  collection. 
Maneuvers such as exercise, steroids, dextran, endotoxins, 
myelosuppressive chemotherapy, and, more recently, the 
use of  recombinant growth factors are shown to increase 
the circulating progenitor cells threefold to lOO-f~ld.~-~~ 
Much effort has been expended to accelerate neutrophil 
and platelet recovery with the hope of  averting infections 
and  hemorrhages,  the  major  causes  of  morbidity  and 
mortality with dose-intensive chemotherapy. Among these 
approaches are cytokines that underwent extensive investi- 
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days. Comparing recovery in the 11 patients to  receive two 
cycles of therapy, the median days to  an absolute neutrophil 
count of 0.1 x  10g/L and 0.5 x  109/L  were not statistically 
significant between the two courses;  neither was there a 
difference  in the incidence of  fever  and  bacteremia.  The 
median number of days to platelet count of 0.02 x  10l2/L 
unmaintained by platelet transfusion was 20 from marrow 
infusion for course 1 and  16 for course 2  (P = .059). The 
median number of days to  a platelet count of 0.05 x  10l2/L 
was significantly shortened: 24 and 19 days for courses 1 and 
2,  respectively  (P = .045). Patients  who received  PBC  re- 
quired fewer number of platelet  transfusions. Extramedullary 
toxicities were not different between the  groups. Our finding 
of enhanced early recovery of platelets and reduced platelet 
transfusion requirement is in concordance with other stud- 
ies. 
0 1992 by  The American Society of Hematology. 
gation in the clinical setting.16-u  They stimulate the prolifer- 
ation and differentiation of  progenitor cells, promote sur- 
vival  of  progenitor  and mature hematopoietic  cells, and 
influence different functions of  the hematopoietic ~ells.2~ 
Used with ABM, they shorten but do not eliminate absolute 
neutropenia (absolute neutrophil count [ANC] <  0.1 x lo9/ 
L).16  PBC  enriched  for  progenitor  cells when  added to 
ABM and growth factors may theoretically ameliorate the 
neutropenic  period.  ABM would provide  stem cells and 
early progenitors, while PBC, more committed progenitors, 
and growth factors hopefully would stimulate differentia- 
tion  and  maturation  of  progenitor  cells.  Gianni  et  al, 
applying all three, PBC collected after high-dose cyclophos- 
phamide and recombinant human granulocyte-macrophage 
colony-stimulating factor (rhGM-CSF), ABM, and rhGM- 
CSF posttransplantation, described impressive hematologic 
recovery.10 Using  the same principle,  yet  in  a  different 
fashion,  we  conducted  a  study  incorporating  all  three 
different modalities, with each patient serving as his or her 
control, to determine whether PBC accelerates hematopoi- 
etic recovery over that of  ABM and growth factors alone 
and whether the effect, if  any, is dramatic enough to ablate 
the  absolute  neutropenic  period.  We  used  ABM  and 
growth factor as support during the first course of high-dose 
chemotherapy and the enriched PBC in addition to ABM 
and  growth  factors  during  the  second  course.  Before 
apheresis, marrow progenitors cells were  mobilized with 
high-dose cyclophosphamide and doxorubicin because of 
the reported rebound increase in the circulating progenitor 
cells after these drugs” and also because of  their activity in 
several human tumors, particularly breast cancer. At the 
completion of  cyclophosphamide and doxorubicin chemo- 
therapy, rhGM-CSF was also administered to maximize the 
mobilization  of  granulocyte-macrophage  colony-forming 
Blood,  Vol79, No 12 (June 15). 1992: pp 3388-3393 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From BLOOD STEM  CELLS-GM-CSF-HIGH-DOSE  THERAPY  3389 
units (CFU-GM) and to reduce the period of  neutropenia 
during the priming therapy. 
Since 1986, we have treated patients with solid tumors 
using double high-dose cyclophosphamide, etoposide, and 
cisplatin  (CVP)  with  meaningful  response  rates  and  a 
significant  proportion  of  long-term  disease-free  survi- 
vor~.~~-~~  We  therefore used  this  double  transplant  ap- 
proach as a model that would allow us to study the effects of 
addition of rhGM-CSF (first and second courses) and PBC 
(second course) to ABM in each patient. 
MATERIALS AND METHODS 
Patients.  Patients with histologically confirmed metastatic solid 
tumors were entered into the study from March 1989 to February 
1990. Patients with estrogen receptor (ER)-negative breast cancer 
or hormonal refractory ER-positive breast cancer were eligible. All 
patients had a performance status (Zubrod scale) 12.  All patients 
had an ejection fraction of  2  50% by cardiac scan, forced expira- 
tory volume in 1  second and a diffusion capacity 2 50% predicted; 
a  serum creatinine  1135  pmol/L  (1.5  mg%)  and  a  creatinine 
clearance of  at least 1.00 mL/s (60 mL/min), and a total bilirubin 
of  less than 35 pmol/L (2 mg%). All patients were negative for 
hepatitis-B  surface  antigen  and  human  immunodeficiency viral 
antibody. Patients with histologic evidence of tumor cells in the BM 
were excluded. 
Patients had  not  been  previously exposed  to nitrosourea  or 
mitomycin. The last chemotherapy, radiotherapy, or immunother- 
apy must have been completed at least 3 weeks before entry into 
this study. All patients were able to undergo general anesthesia for 
bilateral BM harvesting and all had central venous access for PBC 
collection. 
All patients  had history and physical 
examination, complete  blood  count,  differential  count,  platelet 
count, chemical survey, chest radiograph, pulmonary function tests 
including diffusion capacity, multigated cardiac scan, electrocardio- 
gram,  bilateral  BM  aspirates  and  biopsies,  24-hour  creatinine 
clearance,  and  appropriate  tumor  markers.  All  patients  were 
restaged before entry into the study. Computerized tomography of 
the thorax and/or abdomen when deemed necessary were obtained 
to measure sites of  the disease. 
BM  hawest  and  storage.  Technique  was  as  previously  de- 
scribed.26  Before PBC mobilization, all patients had 800 to 1,000 
mL of  BM  harvested  from bilateral  posterior  iliac crests under 
general anesthesia. This was adequate for two courses of  high-dose 
chemotherapy. At least 2 x lo8  nucleated cells/kg body weight and 
a  minimum  postthaw  in  vitro  colony growth  of  2  x  lo4 CFU- 
GM/kg were required for entry into the study. 
PBC  mobilization,  collection,  and  storage.  All  patients  had 
double lumen central venous catheter (Quinton Instrument Com- 
pany,  Seattle,  WA)  inserted  before  priming  therapy.  Priming 
agents consisted of cyclophosphamide 3 g/m2 intravenously (IV) 
on day 1  and doxorubicin at 50  mg/m2  continuous IV infusion over 
48 hours starting day 2. On day 4, rhGM-CSF (GM-CSF Schering, 
Kenilworth, NJ) was started as a 4-hour IV infusion by portable 
infusion pump (Travenol Laboratories,  Incorporated,  Deerfield, 
1L) at a dose of  0.6 mg/m2 for  14 days. When  leukocyte count 
reached 20 x 109/L, the dose of  rhGM-CSF was reduced by 50% 
each day as long as the leukocyte count was maintained above 20 x 
109/L.  PBC collection started on  day 10 to 14  of chemotherapy on  4 
consecutive weekdays, each collection lasting for 4 to 5 hours. 
PBC were collected from patients using continuous flow blood 
cell separator COBE Spectra (COBE Laboratories, Incorporated, 
Lakewood, CO) and Fenwal CS3000 (Baxter Health Care Prod- 
ucts,  Deerfield, IL). Procedure  parameters included the use of 
Pretreatment  evaluation. 
acid-citrate dextrose-A anticoagulant at flow rates calculated to be 
1.4  times  the  patient’s  blood  volume  (calculated  from  height, 
weight, and sex). The ratio of  acid citrate dextrose to whole blood 
was 1:9. Plasma flow rates were computed from patient’s hemat- 
ocrit.  The volume  of  blood  processed  was  twice  the  patient’s 
calculated blood volume and ranged from 6.0 to 12.0 L. Continuous 
calcium chloride, diluted in normal saline was infused IV through a 
rate controlled  pump (IMED Corporation,  San Diego,  CA) to 
prevent citrate-induced  hypocalcemia. After completion of  PBC 
collection, the Quinton  catheter was changed to a double lumen 
subclavian catheter in preparation for high-dose CVP. 
BM  CFU-GM were  determined  by 
culturing 1 x 105 nucleated cells in a double layer semisolid system 
described.”  The assay was performed in triplicates and sealed in 
boxes in a humidified atmosphere at 5% COZ,  12% 02,  and 83% N2 
at 37°C. After 10 days, aggregates of  greater than 40 cells were 
counted  as  colonies.  Peripheral blood  CFU-GM assay was  as 
previously described.28 
As approved by the Institutional Review Board, 
written  informed consents were obtained from all patients.  Pa- 
tients were nursed in private rooms. Vigorous hydration to main- 
tain a high urine output was started 24 hours before chemotherapy 
and continued  for 24 hours after the last day of  chemotherapy. 
Cyclophosphamide 1.75 g/m2  in 250 mL 5% dextrose in water was 
administered IV over 1 hour on days 1, 2,  and 3; etoposide 400 
mg/m2 in normal saline was infused over 4 hours every 12 hours on 
days 1,2,  and 3; and cisplatin 60 mg/m2  in 500 mL of  normal saline 
with 40 g mannitol, 30 mEq KCL, and 8 mEq MgSO4 was infused 
over 2 hours on  days 1,2, and 3. After the third patient, the dose of 
cisplatin  was  reduced  to  55  mg/m2  because  of  the  frequent 
occurrence of  peripheral neuropathy  in another study using this 
same regimen.  Antiemetics  were  routinely  administered  before 
and during high-dose CVP. The second course was administered as 
soon  as the patient’s  ANC was greater than  1.5  x  109/L, the 
platelet  count was greater than  0.1  x  10l2/L, and after all the 
extramedullary toxicities from course one had resolved. 
A  group of  patients  treated with  similar  doses  of  CVP and 
supported  with  ABM  infusion  alone  served  as  our  historical 
control.29 
All patients  were premed- 
icated with hydrocortisone and diphenhydramine  30 minutes IV 
before  autologous marrow  infusion.  Half  of  the  cryopreserved 
ABM was rapidly thawed to 37°C at the patient’s bedside and was 
infused on day 6 of each course of chemotherapy. On day 5 of  each 
course of  CVP,  patients  received  rhGM-CSF at a  dose of  0.6 
mg/m2  IV over  4  hours  until  the  ANC of  1.5  x  109/L was 
maintained for 2 consecutive days, then the dose of  rhGM-CSF is 
halved every day as long as ANC was maintained above 1 x 109/L. 
If  the ANC decreased  below  1 x  109/L when  rhGM-CSF was 
tapered off, the dose of rhGM-CSF will be doubled on  a daily basis 
until the ANC reached  above 1 x  109/L  for 2 consecutive days, 
then gradually reduced. In the second course on  day 6 from start of 
chemotherapy, in addition to the ABM and rhGM-CSF, all of  the 
PBC was rapidly thawed to 37T,  and infused to the patients. 
All  blood  products  were  irradiated  with  25  cGy.  Patients’ 
hemoglobin were kept  above 80 g/L with packed red blood cell 
(RBC) transfusion and platelets above 0.02 x  10l2/L  with single- 
donor or random-donor platelet  transfusions. At the initiation of 
chemotherapy,  all  patients  were  placed  on prophylactic  tri- 
methoprim-sulfamethoxazole and ketoconazole. During the period 
of  neutropenia,  patients with temperature was 38.5”C or higher 
were started immediately on vancomycin and a third-generation 
cephalosporin. 
Median days to recovery of  a given ANC 
and platelet count and the difference in transfusion frequency for 
CFU-GM colony  assay. 
Treatmentplan. 
Stem cell injimon and supportive  care. 
Statistical methods. 
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patients in  the two  arms of  the  study were compared using the 
Wilcoxon signed rank. Differences in the characteristics of  patients 
between the two arms and difference in the number of  febrile days 
and episodes of bacteremia were analyzed by  x2  analysis. AP  value 
<  .05 was considered significant. 
RESULTS 
Fourteen patients were  registered  in the study. Three 
patients  did  not  receive the second  course  of  high-dose 
CVP because of  severe toxicity in one, progressive disease 
in the second, and refusal by the third patient to continue in 
the study, leaving 11 patients evaluable for a comparison of 
hematopoietic recovery for the two courses. Tumor types of 
the evaluable patients were as follows: breast cancer 5, lung 
cancer 3, sarcoma 1, melanoma  1, and adenocarcinoma of 
unknown primary 1. The median age of  the group was 46 
(range, 35  to 65). The median number of  prior cycles of 
chemotherapy was three (range, 0 to 14); one patient had 
prior radiation. One patient underwent two priming courses 
because  of  inadequate mononuclear  cells collected.  All 
patients underwent aphereses and tolerated PBC collection 
without complications. The median number of  aphereses 
was five (range, 4 to 6); each collection lasted for an average 
of  4 hours. The median number of  weeks between the two 
courses for the whole group was 5 weeks. 
With the priming course, the median number of  days to a 
leukocyte count (white blood cell [WBC]) of  1.0 x  109/L 
was 14, to an ANC of  0.1 x 109/L  and to 0.5 x 109/L were 
14 and 15  days, respectively. Three patients had platelet 
count decreased to I  0.02 x 10l2/L. 
Hematopoietic recovery of  the two courses are shown in 
Table 1. The median numbers of  days to an ANC of  0.1 x 
109/L, 0.5  x  109/L, and  1.0  x  109/L from  first  day of 
chemotherapy were 16,18, and 21 (10,12, and 15 from the 
day of  ABM infusion, day 0) with course  1 of  high-dose 
CVP and 16,17, and 18 (10,11, and 12 from ABM + PBC) 
for course 2 of CVP. 
Twenty-three historical controls with comparable charac- 
teristics were  treated in course  1 with  identical doses of 
CVP with ABM support alone.29  When comparing recover- 
ies during the first course using ABM + rhGM-CSF with 
our historical group of  patients, the neutrophil recovery to 
0.1 x 109/L, 0.5 x 109/L,  and 1.0 x 109/L  from the first day 
of  chemotherapy  were  3  days  earlier  (19,  21,  and  24, 
respectively) than with ABM alone. With ABM + rhGM- 
Table 1.  Hematopoietic  Recovery 
Course 1  Course 2 
ABM + GM  ABM + GM + PBC  PValue 
Median days to* ANC (range): 
>0.1 x 109/L  16 (13-20)  16 (1  5-20)  ,262 
>0.5  x 109/L  18 (17-26)  17 (16-23)  .058 
>1.0  x 109/L  21 (17-29)  18 (16-26)  ,138 
Median days to* platelet count (range): 
>0.02  x 10YL  20 (16-28)  16 (13-24)  ,059 
>0.05  x 10YL  24 (18-33)  19 (13-31)  .045 
>0.10  x 10YL  26 (20-35)  29 (1  8-44)  .575 
Abbreviation: GM,  rhGM-CSF. 
*From the first day of chemotherapy. 
Table 2.  Platelet and Packed RBC Transfusions 
Course 1  Course 2 
Patient 
No.  SDP  RDP  TPT  RBC  SDP  RDP  TPT  RBC 
5  20243036 
3  03  3201  13 
12  21  341  124 
9  30343034 
7  40425054 
1  50532024 
2  41582024 
4  23660668 
8  5056 
11  32  512 
14  05  561  12  4 
6  3  4  7  6  3  0  3  10 
10  26841346 
13  11  1  12  8 
Median  3  1  5  5  3  0  3  4 
Abbreviations:  SDP,  single-donor  platelets;  RDP,  random-donor 
platelets; TPT, total platelet transfusions. 
CSF + PBC, the median numbers of  days to an ANC of 
0.1 x  109/L, 0.5 x 109/L, and 1.0 x  109/L  was 1, 3, and 4 
days earlier than with ABM alone.29 
The median number of days to platelet count of  0.02 x 
10l2/L unmaintained by  platelet  transfusion was 20 from 
first day of chemotherapy (14 from ABM) for course 1 and 
16 (10 from ABM + PBC) for course 2, which did not reach 
statistical significance (P = .059). The median number of 
days to a platelet  count of  0.05  x  10l2/L was statistically 
significant; for course 1, 24 days (18 from ABM) and for 
course  2,  19  days  (13  from  ABM)  (P  = .045).  Platelet 
recovery to 0.10 x  10l2/L  was 26 and 29 days for course 1 
and course 2, respectively (P = .575). At our institution, 4 
U of  random-donor  platelets constituted one transfusion. 
In  this  study,  all  patients  uniformly  received  4  U  of 
random-donor platelets for each transfusion. The median 
numbers of platelet transfusions (random-donor and single- 
donor platelets) as shown in Table 2 were five for course 1 
(in all patients and also in those to receive two courses) and 
three for course 2 (P < .05). Except for three patients in 
the  second  course,  all patients  had  shorter duration  of 
platelet count less than 0.02 x  10l2/L  and less than 0.05 x 
10l2/L during the second cofirse than on the first course. 
Seven of  the 11 patients required fewer platelet  transfu- 
sions in the second course than in the first, three required 
more, and one patient  the same. The median number of 
packed RBC transfusions was four for both courses in the 
11 patients who received both  cycles (Table  2).  Platelet 
recovery supported with ABM + rhGM-CSF in course 1 
was not significantly different when compared to the histor- 
ical group supported with ABM alone in course 1 (median 
day to a platelet count of 0.02 x 10l2/L,  0.05 x 10l2/L,  and 
0.10 x  10l2/L  were 19, 21, and 24, respectively). We have 
previously reported the consistent delayed platelet recovery 
after CVP of  the same dose intensity as the current study 
with ABM support alone in course zz9  with median day to 
platelet count of  0.02 x  10l2/L,  0.05 x 10l2/L, and 0.10 x 
10l2/L  being 22,26, and 35, respectively, which are 6,7,  and 
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6 days later than the platelet recovery in this study during 
the second course using ABM + rhGM-CSF + PBC (Table 
1).  There were no major episodes of bleeding. 
During  the first  course,  the median  number  of  cells 
infused in the BM was 1.5 x 108/kg  and the median number 
of  CFU-GM infused was 3.5  x 104/kg. During the second 
course, the median number of cells infused in the BM was 
1.6 x 108/kg and the median number of  CFU-GM infused 
was 3.2 x 104/kg. The median number of peripheral blood 
mononuclear cells and CFU-GM were 1.6 x  loS/kg and 
0.75  x 104/kg.  Nonhematologic toxicities of high-dose CVP 
with rhGM-CSF and stem cell support were not different. 
In decreasing  order, nausea and vomiting, diarrhea,  and 
mucositis were among the most common toxicities. There 
were no treatment-related  deaths. The median number of 
febrile days were 7 (range, 1  to 19) and 7 (range, 0 to 15) for 
courses 1 and 2, respectively. There was one episode of 
gram-negative  bacteremia  and  two  episodes  of  gram- 
positive bacteremia during the priming therapy. There were 
three gram-negative bacteremia in each of  the courses; 5 
and 2  gram-positive  infections  during courses  1 and  2, 
respectively. No fungal infection occurred during the first 
course,  whereas  there  were  two  episodes  of  fungemia 
during the second course. Both patients had no major organ 
involvement  by  fungus  and  infection  cleared  with  the 
administration of Amphotericin-B. 
DISCUSSION 
Fever and infection are directly related to the length of 
time patients have  an ANC of  less than 0.1  x  109/L?0 
Although most studies report ANC recovery to 0.5 x 109/L, 
the most crucial period in neutrophil recovery for resolu- 
tion of  fever after high-dose chemotherapy is probably that 
to greater than 0.1 x  109/L. The onset of  fever generally 
occurs during the first 2 to 5 days of  absolute neutropenia. 
The usual pattern of  neutropenia is a decrease of the ANC 
to below 0.1 x 109/L  on day 8 to 10 after the initiation of 
high-dose chemotherapy, which is 2 days after ABM infu- 
sion followed by an increase to 0.1 x 109/L  on day 19 to 21 
after chemotherapy. Hence, the absolute neutropenic pe- 
riod (0.1 X  109/L)  is approximately 9 to 13 days. Fever and 
serious infections occur before the reappearance of  the first 
neutrophil. Therefore, the goal of  ameliorating fever and 
infection would be best served if  the absolute neutropenia 
(0.1 X 109/L)  could be abrogated. There is no doubt that 
growth  factors  hasten  neutrophil  recovery over  that  of 
ABM infusion alone. They accelerate predominantly the 
terminal part of  neutrophil recovery (ANC to 1 x 109/L). 
Our  as well  as those of  others19,20,31  using growth 
factors with ABM after high-dose chemotherapy, showed 
faster recovery of  ANC to 0.5 X 109/L  and 1 x 109/L  when 
compared  with  controls;  however,  incidence  of  febrile 
episodes and infection was largely unchanged. One study 
reported a decrease in episodes of  bacteremia, although the 
recovery of  ANC to 0.1  x  109/L was similar to that of 
control patientsu The majority of the studies, except that 
of  Nemunaitis et al,32  demonstrated no benefit on platelet 
recovery. With growth factor, early recovery of ANC by only 
4  days still leaves a persistent period of  approximately 7 to 8 
days of absolute neutropenia. 
PBC not only can reconstitute hematopoiesis in lieu of 
ABM after high-dose chemotherapy, but when collected in 
a timely fashion after expansion of  the progenitor cells can 
also accelerate  hematopoietic  recovery. This finding has 
generated interest in the use of  PBC in conjunction with 
ABM and growth factors in the transplant setting. Gianni et 
a1 reported the near attenuation of  the absolute  neutro- 
penic  period  after high-dose  melphalan  and total  body 
irradiation with a combination of  ABM, rhGM-CSF, and 
mobilized PBC collected during the overshoot of hematopoi- 
esis from high-dose cyclophosphamide  and rhGM-CSF.'O 
With this background, we designed this protocol to deter- 
mine in a comparative fashion the contribution of  PBC over 
that of  ABM and growth factors within the same patients in 
the hematopoietic recovery after high-dose chemotherapy. 
Taking advantage of  our extensive experience with double 
high-dose CVP and with the knowledge of  the pattern of 
hematopoietic recovery with this  we used ABM 
and rhGM-CSF with the first CVP while applying primed 
PBC in addition to ABM and rhGM-CSF with the second 
CVP. We have previously shown in a randomized study of 
ABM versus endogenous recovery (no-ABM) using double 
CVP that ABM enhanced neutrophil recovery, particularly 
the early component (ANC to 0.1 x 109/L),  with no signifi- 
cant clinical impact on febrile neutropenic episodes. There 
was a trend, although not significant, towards more rapid 
neutrophil recovery to 0.5 x  109/L  and 1 x  109/L  on the 
ABM arm during the second CVP, suggesting that indeed a 
transfusion product can overcome the depletion of  endoge- 
nous  myeloid  progenitor  cells.  In contrast,  there was  a 
consistent delay in platelet recovery with the second CVP 
with or without ABM.29  Because of  the favorable reports of 
PBC on platelet recovery,2J0  it was hoped that by  adding 
mobilized PBC to the other stem cells (ABM and rhGM- 
CSF), we could  shorten not only the period  of  absolute 
neutropenia but also the period of  thrombocytopenia and 
thereby decrease platelet  transfusion and avoid bleeding 
complications and platelet alloimmunization, which devel- 
ops with multiple platelet transfusions. 
In this study, we confirmed  our initial conjecture  and 
Gianni et al's impression that mobilized PBC enhanced the 
early part of platelet  recovery with resultant reduction in 
platelet transfusion requirement. The fact that rhGM-CSF 
with ABM did not  hasten  platelet  recovery over that of 
patients treated with  same regimen  with  ABM support 
alone and the finding of significantly rapid platelet recovery 
in the second course, which in our historical controls using 
ABM  alone  was  consistently  delayed,  suggest  that  the 
positive effect may be that produced by  PBC rather than 
that by rhGM-CSF. We, however, failed to demonstrate any 
statistically significant difference in neutrophil recovery and 
reduction in the incidence of  infection. 
This transplant  approach is not without problems. The 
performance  of  repeated  aphereses  can  be  costly. The 
therapy for mobilization may not always be appropriate for 
the treatment of the disease. The timing of  the collection of 
PBC may be off resulting in unnecessary aphereses. Siena et 
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a1 described a direct immunofluorescence assay for circulat- 
ing  hematopoietic progenitor cells  (CD34/CD33).33  This 
could aid investigators  in the appropriate time and duration 
of apheresis. The timing of the infusion of  PBC in relation 
to  ABM  infusion  is  also  crucial  and has  not  yet  been 
definitely  established. Another concern is tumor contamina- 
tion  of  the  PBC.  Although  tumor  cells  could  not  be 
detected in the PBC harvest by one  another study 
of  PBC transplant in patients with neuroblastoma reported 
tumor contamination of  PBC collections in a quarter of 
their patients.35  However, there was no correlation between 
bone marrow involvement and contamination of PBC in the 
latter  Long-term follow-up of  patients who undergo 
PBC  transplantation  is warranted.  The  next  important 
question  is  will  the  enhancement  of  platelet  recovery 
continue to be an issue and will the gain of lesser platelet 
transfusions  be  worth  the  risk  of  possible  tumor  cell 
reinfusion and  other  potential negative factors that have yet 
to surface with the increased use of  PBC. The use of  newer 
growth factors may circumvent this problem. Refinement of 
stem cell  support  requires  true  and properly  designed 
comparative trials that will also have to account for all the 
variables in  supportive care such as methods of  nursing 
patients, prophylactic antibiotics, definition of  a significant 
gram-positive culture and other patient variables. 
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